Traders should monitor upcoming sales figures for Exdensur in China and potential uptake dynamics, as this approval opens a large new market. Consider positioning ahead of respiratory segment earnings disclosures. Watch for NMPA decision on Exdensur for CRSwNP, which is under review.
Price Chart
Executive Summary
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype in patients aged 12 and older. The approval is based on SWIFT-1 and SWIFT-2 phase III trials showing significant reductions in asthma exacerbations, with 58% and 48% lower annualized exacerbation rates versus placebo, respectively.
Key Facts
- Exdensur approved in China for severe asthma with eosinophilic phenotype in patients aged 12+
- Approval based on SWIFT-1 and SWIFT-2 phase III trials demonstrating 58% and 48% reduction in annualized exacerbation rates versus placebo
- Exdensur is the first and only ultra-long-acting biologic in China with twice-yearly dosing for this indication
- More than 2 million people in China suffer from severe asthma
- Exdensur already approved in the US, EU, UK, and Japan for severe asthma and/or CRSwNP
Financial Impact
Potential for meaningful revenue growth in a high-burden, underserved market; China represents a major commercial opportunity given 46M adults with asthma and limited biologic options
Risk Factors
- Commercial execution risk in China including pricing, reimbursement, and market access
- Competition from existing biologics despite Exdensur's twice-yearly dosing advantage
- Forward-looking statements include caution about actual results differing due to risks and uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-002916 |
| Document: 0001654954-26-002916-index-headers.html | 0001654954-26-002916 |
| Document: 0001654954-26-002916-index.html | 0001654954-26-002916 |
| Document: 0001654954-26-002916.txt | 0001654954-26-002916 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access